More Alterity Therapeutics Ltd. news
Alterity Therapeutics Ltd.ASX: ATH

Prana to commence Phase 1 clinical trial of PBT434

Jun 13, 2018 at 11:59 PM EDT · Issued by Alterity Therapeutics Ltd.

Filed with ASX · Jun 13, 2018 at 11:59 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/prana-to-commence-phase-1-clinical-trial-of-pbt434

Alterity Therapeutics Ltd. on 6ix

Earlier from Alterity Therapeutics

  • PBT434 at the 6th International Multiple System Atrophy ConfMar 6, 2018
  • Prana receives $3 million R&D Tax Incentive RefundDec 18, 2017
  • Prospectus SupplementNov 8, 2017
  • Notice of Meeting/ Proxy FormOct 13, 2017
  • Appendix 4E and Annual ReportAug 31, 2017

Later from Alterity Therapeutics

  • First Volunteers Dosed in Phase I Clinical Trial of PBT434Jul 3, 2018
  • Prana to present PBT434 data at International CongressJul 8, 2018
  • Annual Report to shareholdersAug 31, 2018
  • New data show potential for PBT434 to treat MSAOct 5, 2018
  • Life Bioscience LLC leads strategic investment upto A$44.5MDec 27, 2018
All Alterity Therapeutics news releases↗

Follow Alterity Therapeutics into a list and get an email when it puts out news.

Follow Alterity Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer